Risk factors for rituximab-induced interstitial lung diseases in patients with malignant lymphoma

MeSH terms

• Age Factors
• Antibodies, Monoclonal, Murine-Derived / administration & dosage
• Antibodies, Monoclonal, Murine-Derived / adverse effects*
• Antineoplastic Agents / administration & dosage
• Antineoplastic Agents / adverse effects*
• Humans
• Lung Diseases, Interstitial / chemically induced*
• Lymphoma, Non-Hodgkin / drug therapy*
• Multivariate Analysis
• Retrospective Studies
• Risk Factors
• Rituximab
• Severity of Illness Index